Novo And Lilly Push Beyond US As Only 1%-2% Use Obesity Drugs Globally

Novo Nordisk (NVO) and Eli Lilly (LLY) are preparing for the next stage of the obesity-drug race, with both companies looking beyond the US for growth as cost r